Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology Scientific Presentation at the Medical University of Warsaw

AURORA, ON--(Marketwired - Jun 27, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ) ("Helix" or the "Company"), a immune-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that Helix's Chief Scientific Officer, Dr. Heman Chao will be making a presentation on Tuesday, June 28, 2016 at the Strategies Towards Excellence in Immuno-Oncology symposium at the Medical University of Warsaw in Poland.

Dr. Chao's presentation entitled, Therapeutic Strategy Against Tumour Acidity Induced Immune-Suppression , will discuss the potential benefits of Helix's DOS47 platform in the treatment of cancer. The slide portion of the presentation will be made available on Helix's website for viewing at www.helixbiopharma.com .

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential benefits of Helix's DOS47 platform in the treatment of cancer. Forward-looking statements, which may be identified by words including, without limitation, "will", "potential", "benefits" and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. 

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Email: ir@helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 149

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 469

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 92

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading

Top 5 Most Recently Viewed Articles

AAVantgarde's Professor Auricchio Receives Prestigious Role

Updated Category News Views 177

AAVantgarde's Professor Auricchio Achieves New Milestone MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to...

Continue Reading
How Bitcoin's Drop Affects Strategy Inc (NASDAQ: MSTR) Investors

Updated Category News Views 137

Understanding the Current Market Landscape As recent market trends demonstrate, Strategy Inc (NASDAQ: MSTR) is seeing significant activity. On one hand, the company is evidently reliant on the performance of Bitcoin. With such dependence, the fluctuations in the value of Bitcoin are crucial to the health of MSTR. This situation poses both risks and opportunities for...

Continue Reading
Significant Attorney Departures to Strengthen Association Law Firm

Updated Category News Views 99

Major Attorney Moves to Association Law Group (ALG) In a noteworthy shift within Florida's community association law landscape, several prominent attorneys have transitioned from Becker & Poliakoff to join the ranks of Association Law Group (ALG). Among them, Michael C. Gongora, Lilliana Farinas-Sabogal, and Adam Cervera are recognized for their extensive experience in...

Continue Reading
EQB's Commitment to Sustainability in Financial Services

Updated Category News Views 175

EQB Focuses on Sustainability in Its Latest Report EQB Inc. (TSX: EQB) has recently published a detailed Responsibility Report, highlighting significant strides towards its sustainability commitments. This annual report encapsulates the company's dedication to fostering an environment of innovation within the Canadian banking sector, with a particular focus on enriching...

Continue Reading
BofA's Downgrade of Sandvik: Navigating Market Pressures Ahead

Updated Category News Views 103

BofA Securities dropped a bomb on Sandvik AB back then by downgrading it from Neutral to Underperform. This move sent shockwaves through the trading floor, mainly because they saw some serious trouble brewing in Sandvik’s Machining and Manufacturing Solutions (SMMS) division. Traders were quick to pick up on the whispers about short cycle pressures that could really...

Continue Reading